AVA

BIOLOGICAL4 trials

Sponsors

PharmAthene UK Limited, Emergent BioSolutions, University of Zurich

Conditions

Anthrax InfectionBacillus Anthracis (Anthrax)Early PregnancyFertility DisordersInfections, Bacterial

Phase 1

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

CompletedNCT01979406

Emergent BioSolutionsAnthrax Infection

Start: 2013-11-30End: 2015-09-30Updated: 2024-03-18

Phase 2

Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

CompletedNCT00170469

PharmAthene UK LimitedBacillus Anthracis (Anthrax)

Start: 2005-03-31End: 2007-02-28Updated: 2008-09-15

Phase 4

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

CompletedNCT02339155

Emergent BioSolutionsInfections, Bacterial

Start: 2015-02-24End: 2017-06-06Updated: 2024-03-18

Unknown Phase

Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)

CompletedNCT03161873

University of ZurichEarly Pregnancy, Fertility Disorders

Start: 2016-11-30End: 2020-11-30Updated: 2022-09-28

Related Papers

Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.

2020-04-2212 citations